




Patent Application  
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28<sup>th</sup> day of May, 2004.

By

  
(Signature of person mailing)  
Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith

:

APPLICATION NO.: 10/763,105

: Examiner: To be Assigned

FILING DATE: January 21, 2004

: Group Art Unit: To be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: May 28, 2004

  
Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 1/21/04		GROUP Not Available		
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 20010027193 A1	10/04/01	Achard, et al.			
	US 20010053788 A1	12/20/01	Lange, et al.			
	US 20020019383 A1	02/14/02	Achard, et al.			
	US 20020019421 A1	02/14/02	Biberman, et al.			
	US 20020035102 A1	03/21/02	Achard, et al.			
	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
	US 20020119972 A1	08/29/02	Leftheris, et al.			
	US 20020128302 A1	09/12/02	Maruani, et al.			
	US 20020188007 A1	12/12/02	Barth, et al.			
	US 20030003145 A1	01/02/03	Abramovici, et al.			
	US 20030055033 A1	03/20/03	Achard, et al.			
	US 20030114495 A1	06/19/03	Finke, et al.			
	US 20030139386 A1	07/24/03	Cote, et al.			
	US 20030199536 A1	10/23/03	Thomas, et al.			
	US 20040077650 A1	4/22/04	Dow			
	US 20040092520 A1	5/12/04	Griffith			
	US 4,925,846	05/15/90	Deacon, et al.			
	US 4,944,790	07/31/90	Moser, et al.			
	US 5,134,142	07/28/92	Matsuo, et al.			
	US 5,462,960	10/31/95	Barth, et al.			
	US 5,596,106	01/21/97	Cullinan, et al.			
	US 5,624,941	04/29/97	Barth, et al.			
	US 5,744,491	04/28/98	Boigegrain, et al.			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 1/21/04		GROUP Not Available		
	US 5,744,493	04/28/98	Boigegrain, et al.			
	US 5,747,524	05/05/98	Cullinan, et al.			
	US 5,925,768	07/20/99	Barth, et al.			
	US 6,028,084	02/22/00	Barth, et al.			
	US 6,100,259	08/08/00	Xiang, et al.			
	US 6,344,474 B1	02/05/02	Maruani, et al.			
	US 6,355,631 B1	03/12/02	Bouchard, et al.			
	US 6,432,984 B1	08/13/02	Barth, et al.			
	US 6,476,060 B2	11/05/02	Lange, et al.			
	US 6,479,479 B2	11/12/02	Achard, et al.			
	US 6,509,367 B1	01/21/03	Martin, et al.			
	US 6,518,264 B2	02/11/03	Achard, et al.			
	US 6,566,356 B2	05/20/03	Achard, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>						
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
✓ CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
✓ US 2003087933 equiv. to WO 01/58450 A2	08/16/01	PCT				
✓ US 5051518 equiv. to EP 293,220 B1	8/31/94	EP				
✓ US 6642258 equiv. to WO 01/24798 A1	04/12/01	PCT				
✓ WO 00/15609 A1	05/23/00	PCT				X
✓ WO 01/029007 A1	04/26/01	PCT				
✓ WO 01/032629 A1	05/10/01	PCT				X
✓ WO 01/032663 A2	05/10/01	PCT				X
✓ WO 01/85092 A2	11/15/01	PCT				X
✓ WO 02/076949 A1	10/03/02	PCT				

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 1/21/04		GROUP	Not Available	
<input checked="" type="checkbox"/>	WO 03/006007 A1	01/23/03	PCT			
<input checked="" type="checkbox"/>	WO 03/007887 A2	01/30/03	PCT			
<input checked="" type="checkbox"/>	WO 03/018060 A1	03/06/03	PCT			X
<input checked="" type="checkbox"/>	WO 03/020217 A2	03/13/03	PCT			
<input checked="" type="checkbox"/>	WO 03/020314 A1	03/13/03	PCT			X
<input checked="" type="checkbox"/>	WO 03/026647 A1	04/03/03	PCT			
<input checked="" type="checkbox"/>	WO 03/026648 A1	04/03/03	PCT			
<input checked="" type="checkbox"/>	WO 03/027069 A1	04/03/03	PCT			
<input checked="" type="checkbox"/>	WO 03/027076 A2	04/03/03	PCT			
<input checked="" type="checkbox"/>	WO 03/027114 A1	04/03/03	PCT			
<input checked="" type="checkbox"/>	WO 03/040107 A1	05/15/03	PCT			
<input checked="" type="checkbox"/>	WO 03/051850 A1	06/26/03	PCT			
<input checked="" type="checkbox"/>	WO 03/051851 A1	06/26/03	PCT			
<input checked="" type="checkbox"/>	WO 03/075660 A1	09/18/03	PCT			
<input checked="" type="checkbox"/>	WO 03/077847 A2	09/25/03	PCT			
<input checked="" type="checkbox"/>	WO 03/078413 A1	09/25/03	PCT			
<input checked="" type="checkbox"/>	WO 03/082190 A2	10/09/03	PCT			
<input checked="" type="checkbox"/>	WO 03/082191 A2	10/09/03	PCT			
<input checked="" type="checkbox"/>	WO 03/082256 A2	10/09/03	PCT			X
<input checked="" type="checkbox"/>	WO 03/082833 A1	10/09/03	PCT			X
<input checked="" type="checkbox"/>	WO 03/084943 A2	10/16/03	PCT			X
<input checked="" type="checkbox"/>	WO 03/086288 A2	10/23/03	PCT			
<input checked="" type="checkbox"/>	WO 03/087037 A1	10/23/03	PCT			
<input checked="" type="checkbox"/>	WO 04/012617 A2	02/12/04	PCT			
<input checked="" type="checkbox"/>	WO 96/02248 A1	02/01/96	PCT			

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105	
			APPLICANT DAVID A. GRIFFITH		
			FILING DATE 1/21/04	GROUP	Not Available
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
			<input checked="" type="checkbox"/> Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , <b>138</b> , 544-553 (2003).		
			<input checked="" type="checkbox"/> Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , <b>23</b> (6), 2453-2458 (2003).		
			<input checked="" type="checkbox"/> Croci, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- $\alpha$ in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , <b>140</b> , 115-122 (2003).		
			<input checked="" type="checkbox"/> DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Let</u> , <b>349</b> , 49-52 (2003).		
			<input checked="" type="checkbox"/> Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , <b>100</b> (3), 1393-1398 (2003).		
			<input checked="" type="checkbox"/> Ruiu, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , <b>306</b> , 363-370 (2003).		
			<input checked="" type="checkbox"/> Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , <b>54</b> , 161-202 (2002).		
			<input checked="" type="checkbox"/> Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , <b>22</b> (21), 9612-9617 (2002).		
			<input checked="" type="checkbox"/> Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , <b>296</b> (3), 1013-1022 (2001).		
			<input checked="" type="checkbox"/> Lellement, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , <b>25</b> (9), 1317-1323 (2001).		
			<input checked="" type="checkbox"/> Pertwee, R.G., "Cannabinoids and the Gastronintestinal Tract," <u>Gut</u> , <b>48</b> , 859-867 (2001).		
			<input checked="" type="checkbox"/> Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , <b>9</b> (7), 1573-1571 (2000).		
			<input checked="" type="checkbox"/> Hungund, B.L and B.S. Basavarajappa, "Are Anandamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol &amp; Alcoholism</u> , <b>35</b> (2) 126-133, (2000).		
			<input checked="" type="checkbox"/> Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , <b>67</b> , 265-270 (2000).		
			<input checked="" type="checkbox"/> Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem</u> , <b>42</b> , 769-776 (1999).		
			<input checked="" type="checkbox"/> Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem</u> , <b>6</b> , 635-664 (1999).		
			<input checked="" type="checkbox"/> Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res</u> , <b>793</b> , 212-218 (1998).		
			<input checked="" type="checkbox"/> Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap</u> , <b>285</b> , 285-292 (1998).		
			<input checked="" type="checkbox"/> Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci</u> , <b>63</b> , PL113-PL117 (1998);		
			<input checked="" type="checkbox"/> Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoset," <u>Behav. Pharmacol.</u> , <b>9</b> , 179-181 (1998).		
			<input checked="" type="checkbox"/> Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , <b>135</b> , 324-332 (1998).		
			<input checked="" type="checkbox"/> Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol</u> , <b>132</b> , 104-106 (1997).		

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105
			APPLICANT DAVID A. GRIFFITH	
			FILING DATE 1/21/04	GROUP Not Available
			Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <i>Eur J Pharmacol</i> , <b>328</b> , 207-215 (1997).	
			Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <i>Neurosci Let</i> , <b>223</b> , 125-128 (1997).	
			Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Slices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <i>J Pharmacol Exp Ther</i> , <b>277</b> , 1431-1436 (1996).	
			Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <i>J Pharmacol Exp Ther</i> , <b>277</b> , 586-594 (1996).	
			Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <i>Psychopharmacology</i> , <b>124</b> , 315-322 (1996).	
			Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <i>Psychopharmacology</i> , <b>126</b> , 125-131 (1996).	
			Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <i>Behavioral Pharmacology</i> , <b>7</b> , 65-71 (1996).	
			Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <i>Life Sci</i> , <b>56</b> , 1941-1947 (1995).	
			Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <i>Life Sci</i> , <b>56</b> , 1949-1955 (1995).	
			Rinaldi-Carmona, M., et al., "SR141716A, a Patent and Selective Antagonist of the Brain Cannabinoid Receptor," <i>FEBS Letters</i> , <b>350</b> , 240-244 (1994).	
			Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A," <i>Med. Chem. Rev.</i> <b>5</b> , 54-62 (1994).	
			Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <i>J. Med. Chem.</i> , <b>32</b> , 2116-2128 (1989).	
			Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <i>J. Heterocyclic Chem</i> , <b>26</b> , 1389 (1989).	
			Dewey, W.L. "Cannabinoid Pharmacology," <i>Pharmacological Reviews</i> , <b>38</b> (2)m 151-178 (1986).	
			Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophylic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <i>Tetrahedron</i> , <b>39</b> (1) 129-136 (1983).	
			Birkofe, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <i>Chem. Ber.</i> <b>112</b> , 2829-2836 (1979).	
			Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <i>Chem. Ber.</i> <b>112</b> , 3623-3636 (1979).	
			Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsaure-dimethylester" <i>Chem. Ber.</i> <b>112</b> , 1712-1718 (1979).	
EXAMINER			DATE CONSIDERED	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				